Jun 08, 2021 / 02:30PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone, and thank you for joining us. I'm Salveen Richter, a biotechnology analyst at Goldman Sachs, and we're really pleased to have Alnylam here with us. And with us from Alnylam, we have John Maraganore, CEO of the company.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPWith that, John, to start, can you review your P5x25 vision for 2025? And just comment on how you attain your goal of becoming a top 5 biotech company?
John M. Maraganore - Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Yes. Well, Salveen, first of all, thanks for having us. Always a pleasure to be at this meeting even when it's virtual. So the P5x25 vision for Alnylam really is part of a decade-long heritage of setting 5-year goals at our company.
We first started with Alnylam 5x15, which we launched in early 2011 and then Alnylam 2020, which we launched in early 2015. And this
Trustpilot
